Androgen-receptor defect abolishes sex differences in nitric oxide and reactivity to vasopressin in rat aorta.
Contractions of rat thoracic aorta to vasopressin (VP) are threefold higher in females (F) than in males (M), primarily because nitric oxide (NO) attenuation of contraction is greater in M. To determine the role of the androgen receptor (AR) in this mechanism, vascular reactivity to VP was examined in thoracic aorta of the testicular-feminized male (Tfm) rat, which has an X-linked, recessive defect in AR function in affected M. Maximal contraction of normal aortas to VP was fourfold higher in F (4,128 +/- 291 mg/mg ring wt) than in M (971 +/- 133 mg); maximal response of Tfm (3,967 +/- 253 mg) was similar to that of normal F. N(G)-nitro-L-arginine methyl ester increased maximal response to VP threefold in M but had no effect in F or Tfm. In contrast, maximal contraction of normal aortas to phenylephrine was 43% higher in M (4,011 +/- 179 mg) than in F (2,809 +/- 78 mg); maximal response of Tfm (2,716 +/- 126 mg) was similar to that of normal F. N(G)-nitro-L-arginine methyl ester increased maximal response to phenylephrine by >50% in F and Tfm but had no effect in M. Maximal contractile response to 80 mM KCl did not differ among M, F, or Tfm. Thus androgens and normal vascular AR function are important in the greater NO-mediated attenuation of reactivity to VP in M than in F rat aorta, which may involve specific modulation of endothelial VP signal transduction pathways and NO release by androgens. These data also establish the importance of the Tfm rat as a model to study the effects of androgens on cardiovascular function.
Stallone
J N
JN
Department of Veterinary Physiology and Pharmacology, College of Veterinary Medicine, Michael E. DeBakey Institute for Comparative Cardiovascular Sciences, Texas A&M University, College Station, TX 77843, USA. jstallone@cvm.tamu.edu
Salisbury
R L
RL
Fulton
C T
CT
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D013734:Androgen-Insensitivity Syndrome / Q000235:genetics; D000818:Animals; D001011:Aorta / Q000187:drug effects* / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D005808:Genes, Recessive; D008040:Genetic Linkage; D066298:In Vitro Techniques; D008297:Male; D009154:Mutation / Q000502:physiology*; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009569:Nitric Oxide / Q000502:physiology*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D009994:Osmolar Concentration; D010656:Phenylephrine / Q000494:pharmacology; D051381:Rats; D011922:Rats, Mutant Strains; D011944:Receptors, Androgen / Q000235:genetics*; D012016:Reference Values; D012727:Sex Characteristics; D014661:Vasoconstriction / Q000502:physiology; D014667:Vasopressins / Q000494:pharmacology*
D000316:Adrenergic alpha-Agonists; D004791:Enzyme Inhibitors; D011944:Receptors, Androgen; D014667:Vasopressins; D010656:Phenylephrine; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase; D019331:NG-Nitroarginine Methyl Ester